Abstract

Cross-presentation of endocytosed antigen as peptide/class I major histocompatibility complex complexes plays a central role in the elicitation of CD8+ T cell clones that mediate anti-viral and anti-tumor immune responses. While it has been clear that there are specific subsets of professional antigen presenting cells capable of antigen cross-presentation, identification of mechanisms involved is still ongoing. Especially amongst dendritic cells (DC), there are specialized subsets that are highly proficient at antigen cross-presentation. We here present a focused survey on the cell biological processes in the endosomal pathway that support antigen cross-presentation. This review highlights DC-intrinsic mechanisms that facilitate the cross-presentation of endocytosed antigen, including receptor-mediated uptake, maturation-induced endosomal sorting of membrane proteins, dynamic remodeling of endosomal structures and cell surface-directed endosomal trafficking. We will conclude with the description of pathogen-induced deviation of endosomal processing, and discuss how immune evasion strategies pertaining endosomal trafficking may preclude antigen cross-presentation.

Highlights

  • Major histocompatibility complex (MHC) restriction of T lymphocytes was first reported by Doherty and Zinkernagel (1975).They provided experimental proof that T cells can only respond to peptide antigens when they are presented in complex with host-derived MHC molecules, existing in a class I and class II variant

  • CONCLUDING REMARKS Efficient cross-presentation of CD8+ T cells that initiates balanced anti-viral and anti-tumor immune responses depends on dendritic cells (DC)-intrinsic mechanisms that enable the sequential interaction of specific TCR molecules with peptide/MHC complexes in the context of activating or inhibiting signals

  • The molecular mechanisms described in this review all aid to ensure the quantity and quality of this DC-derived signal toward the CD8+ T cells

Read more

Summary

Introduction

Major histocompatibility complex (MHC) restriction of T lymphocytes was first reported by Doherty and Zinkernagel (1975). They provided experimental proof that T cells can only respond to peptide antigens when they are presented in complex with host-derived MHC molecules, existing in a class I and class II variant. MHC and exogenous antigen on class II MHC is not absolute. He demonstrated that minor histocompatibility antigens from transplanted cells (e.g., exogenous antigen) could prime cytotoxic CD8+ T cells in a host class I MHC-restricted manner and named this process cross-priming. The capability to present exogenous antigens via class

Objectives
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.